SEC Form 4
------------

## FORM 4

Check this box if no longer subject

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

		Filed	Pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										
1. Name and Addre Gallagher Ca	ess of Reporting Per	son*	2. Issuer Name <b>and</b> Ticker or Trading Symbol Zentalis Pharmaceuticals, Inc. [ZNTL]		all applicabl Director	10% Ow		her					
(Last) (First) (Middle) C/O ZENTALIS PHARMACEUTICALS, INC. 530 SEVENTH AVENUE, SUITE 2201			3. Date of Earliest Transaction (Month/Day/Year) 11/05/2021		Officer (giv below)	ve title	Other (speci below)	specny					
(Street) NEW YORK	NY	10018	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi Line) X	Form filed	oint/Group Filing (Check Applicabl led by One Reporting Person led by More than One Reporting							
(City)	(State)	(Zip)			FEISOII								

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	mount (A) or (D) Price		Transaction(s) (Instr. 3 and 4)	(1150.4)	(Instr. 4)
Common Stock	11/05/2021		S <sup>(1)</sup>		2,506	D	<b>\$82.0933</b> <sup>(2)</sup>	454,697	D	
Common Stock	11/05/2021		S <sup>(1)</sup>		5,094	D	\$82.9758 <sup>(3)</sup>	449,603	D	
Common Stock	11/05/2021		S <sup>(1)</sup>		2,400	D	\$83.786 <sup>(4)</sup>	447,203	D	

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(e.g., puis, cans, warrants, options, convertible securities)											,					
	1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(S) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

#### Explanation of Responses:

1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021.

2. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from \$81.47 to \$82.43. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from \$82.51 to \$83.50. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from \$83.54 to \$83.99. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

# By: /s/ Melissa B. Epperly,

Attorney-in-Fact for Cam S. 11/05/2021 Gallagher

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.